Moleculin Biotech, Inc. (MBRX) vs Vivos Therapeutics, Inc. (VVOS)
A side-by-side comparison of Moleculin Biotech, Inc. and Vivos Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MBRX
Moleculin Biotech, Inc.
$0.45HealthcareDelayed quote: Oct 6, 2026, 3:04 PM EDT
VVOS
Vivos Therapeutics, Inc.
$0.16HealthcareDelayed quote: Oct 6, 2026, 3:03 PM EDT
Total return — MBRX vs VVOS
growth of $100 · dividends reinvested · last 6yMBRX -100.0% (-74.7%/yr)VVOS -99.9% (-70.3%/yr)VVOS compounded faster over this window
MBRX VVOS
MBRX vs VVOS: by the numbers
- •MBRX is the larger company ($2M vs $2M market cap).
- •Both run net losses; MBRX's is the smaller (0.00% vs -122.42% net margin).
Metrics side by side
Valuation
| Metric | MBRX | VVOS |
|---|---|---|
| P/S ratio | N/A | 0.10 |
| P/B ratio | 0.21 | N/A |
Profitability
| Metric | MBRX | VVOS |
|---|---|---|
| Gross margin | 0.00% | 59.72% |
| Operating margin | 0.00% | -107.92% |
| Net margin | 0.00% | -122.42% |
| ROE | -261.73% | N/A |
| ROIC | -242.25% | -182.30% |
Growth (annualized)
| Metric | MBRX | VVOS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.52% |
| Total return CAGR (5Y) | -78.48% | -72.60% |
Frequently asked
- How have MBRX and VVOS total returns compared?
- Over the past 5 years, MBRX delivered -78.48% and VVOS delivered -72.60% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.